View Future GrowthDBV Technologies 過去の業績過去 基準チェック /06DBV Technologiesの収益は年間平均-4.4%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間17% 2.4%割合で 増加しています。主要情報-4.39%収益成長率20.05%EPS成長率Biotechs 業界の成長-14.59%収益成長率2.40%株主資本利益率-80.54%ネット・マージン-2,919.23%次回の業績アップデート29 Jul 2026最近の業績更新Reported Earnings • May 05First quarter 2026 earnings released: US$0.11 loss per share (vs US$0.26 loss in 1Q 2025)First quarter 2026 results: US$0.11 loss per share. Net loss: US$47.6m (loss widened 76% from 1Q 2025). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.お知らせ • Apr 11+ 2 more updatesDBV Technologies S.A. to Report Q3, 2026 Results on Oct 28, 2026DBV Technologies S.A. announced that they will report Q3, 2026 results on Oct 28, 2026Reported Earnings • Mar 29Full year 2025 earnings released: US$1.05 loss per share (vs US$1.17 loss in FY 2024)Full year 2025 results: US$1.05 loss per share. Net loss: US$146.9m (loss widened 29% from FY 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.Reported Earnings • Oct 31Third quarter 2025 earnings released: US$0.24 loss per share (vs US$0.32 loss in 3Q 2024)Third quarter 2025 results: US$0.24 loss per share. Net loss: US$33.2m (loss widened 8.9% from 3Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Europe.すべての更新を表示Recent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • May 05First quarter 2026 earnings released: US$0.11 loss per share (vs US$0.26 loss in 1Q 2025)First quarter 2026 results: US$0.11 loss per share. Net loss: US$47.6m (loss widened 76% from 1Q 2025). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.Breakeven Date Change • May 04The 6 analysts covering DBV Technologies previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 2.8% per year to 2027. The company is expected to make a profit of US$77.5m in 2028. Average annual earnings growth of 72% is required to achieve expected profit on schedule.お知らせ • May 01DBV Technologies S.A., Annual General Meeting, Jun 03, 2026DBV Technologies S.A., Annual General Meeting, Jun 03, 2026. Location: 107 avenue de la republique, chatillon FranceBoard Change • Apr 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 11+ 2 more updatesDBV Technologies S.A. to Report Q3, 2026 Results on Oct 28, 2026DBV Technologies S.A. announced that they will report Q3, 2026 results on Oct 28, 2026Reported Earnings • Mar 29Full year 2025 earnings released: US$1.05 loss per share (vs US$1.17 loss in FY 2024)Full year 2025 results: US$1.05 loss per share. Net loss: US$146.9m (loss widened 29% from FY 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.Board Change • Mar 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Mar 02Dbv Technologies Highlights Additional Data from Successful Phase 3 Vitesse Study At the Aaaai 2026 Annual MeetingDBV Technologies announced that the company shared additional positive data from the successful Phase 3 VITESSE clinical trial as an oral presentation at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting, in Philadelphia, PA. VITESSE, the food allergy immunotherapy trial to date, is a Phase 3 study assessing DBV's VIASKIN®? Peanut Patch for the treatment of peanut-allergic children aged 4 to 7 years. The VITESSE study met its primary endpoint whereby VIASKIN®?Peanut demonstrated a statistically significant treatment effect (pp. The increases in eliciting dose seen are clinically meaningful and may reflect a reduced risk of an allergic reaction. Conversely, nearly four times as many children on placebo saw their eliciting dose decrease, becoming more sensitized over the twelve-month period. These results not only support the VIASKIN®? peanut Patch as a potential treatment option for peanut-allergic children, if approved, but also reinforce the importance of prioritizing a proactive treatment for this specific patient population.Board Change • Dec 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Nov 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Nov 04DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial, Effective November 3, 2025DBV Technologies announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin(R) Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA submission for 1-3 year-olds in the second half of the year. Kevin Trapp is an accomplished commercial executive with more than 30 years of experience in the biopharmaceutical industry. Before rejoining DBV, Kevin served as a consultant to the Company in his most recent role as Managing Director at Biotech Value Advisors (BVA) where he advised biotechnology boards of directors and executive leadership with product strategy, launch planning, and business evaluation. He built his career at Bristol-Myers Squibb (BMS), where he held roles of increasing responsibility across finance, sales, marketing, and general management. During his time at BMS, he managed a ~$4 billion U.S. specialty and primary care portfolio and was a key stakeholder in the planning and subsequent launches of more than 10 products and indications - including Abilify(R), Atripla(R), Reyataz(R), Orencia(R), and Daklinza(R). Mr. Trapp earned a bachelor's degree from the University of Connecticut School of Business and completed the General Management Program from the European Centre for Executive Development (CEDEP) at INSEAD.New Risk • Oct 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$98m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$98m free cash flow). Shares are highly illiquid. Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$81m net loss in 3 years).Reported Earnings • Oct 31Third quarter 2025 earnings released: US$0.24 loss per share (vs US$0.32 loss in 3Q 2024)Third quarter 2025 results: US$0.24 loss per share. Net loss: US$33.2m (loss widened 8.9% from 3Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Europe.Board Change • Oct 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Oct 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Sep 19DBV Technologies Announces Resignation of Daniel Soland as a Member of its Board of Directors, Effective September 18, 2025DBV Technologies announced the resignation of Daniel Soland, as a member of its Board of Directors, effective September 18, 2025.収支内訳DBV Technologies の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史XTRA:DBV 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 266-1674512931 Dec 256-1473611730 Sep 256-1252910330 Jun 254-122289831 Mar 254-114298931 Dec 244-114318930 Sep 2413-102348330 Jun 2414-88337331 Mar 2415-80336631 Dec 2316-73326030 Sep 236-101317730 Jun 235-101297831 Mar 234-100267931 Dec 225-96267630 Sep 229-71245830 Jun 228-77295931 Mar 225-85326031 Dec 216-98357030 Sep 212-124398530 Jun 214-131389431 Mar 219-148379631 Dec 2011-1604510230 Sep 2017-1615410030 Jun 2016-1716310231 Mar 2016-1697411031 Dec 1915-1727511130 Sep 1912-1767711230 Jun 1913-1989012231 Mar 1913-1918711931 Dec 1813-1908712030 Sep 1811-1787711730 Jun 1811-1726811831 Mar 1811-1826912631 Dec 1712-1776412430 Sep 1711-1696311930 Jun 1711-1576110931 Mar 179-135549131 Dec 168-121518130 Sep 168-109477230 Jun 168-88395931 Mar 168-72315031 Dec 157-49203630 Sep 156-40163130 Jun 156-301125質の高い収益: DBVは現在利益が出ていません。利益率の向上: DBVは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: DBVは利益が出ておらず、過去 5 年間で損失は年間4.4%の割合で増加しています。成長の加速: DBVの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: DBVは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 7.2% ) と比較することは困難です。株主資本利益率高いROE: DBVは現在利益が出ていないため、自己資本利益率 ( -80.54% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/01 10:49終値2026/05/29 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DBV Technologies S.A. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Tazeen AhmadBofA Global ResearchKristen KluskaCantor Fitzgerald & Co.Jonathan WollebenCitizens JMP Securities, LLC13 その他のアナリストを表示
Reported Earnings • May 05First quarter 2026 earnings released: US$0.11 loss per share (vs US$0.26 loss in 1Q 2025)First quarter 2026 results: US$0.11 loss per share. Net loss: US$47.6m (loss widened 76% from 1Q 2025). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
お知らせ • Apr 11+ 2 more updatesDBV Technologies S.A. to Report Q3, 2026 Results on Oct 28, 2026DBV Technologies S.A. announced that they will report Q3, 2026 results on Oct 28, 2026
Reported Earnings • Mar 29Full year 2025 earnings released: US$1.05 loss per share (vs US$1.17 loss in FY 2024)Full year 2025 results: US$1.05 loss per share. Net loss: US$146.9m (loss widened 29% from FY 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
Reported Earnings • Oct 31Third quarter 2025 earnings released: US$0.24 loss per share (vs US$0.32 loss in 3Q 2024)Third quarter 2025 results: US$0.24 loss per share. Net loss: US$33.2m (loss widened 8.9% from 3Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Europe.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • May 05First quarter 2026 earnings released: US$0.11 loss per share (vs US$0.26 loss in 1Q 2025)First quarter 2026 results: US$0.11 loss per share. Net loss: US$47.6m (loss widened 76% from 1Q 2025). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
Breakeven Date Change • May 04The 6 analysts covering DBV Technologies previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 2.8% per year to 2027. The company is expected to make a profit of US$77.5m in 2028. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
お知らせ • May 01DBV Technologies S.A., Annual General Meeting, Jun 03, 2026DBV Technologies S.A., Annual General Meeting, Jun 03, 2026. Location: 107 avenue de la republique, chatillon France
Board Change • Apr 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 11+ 2 more updatesDBV Technologies S.A. to Report Q3, 2026 Results on Oct 28, 2026DBV Technologies S.A. announced that they will report Q3, 2026 results on Oct 28, 2026
Reported Earnings • Mar 29Full year 2025 earnings released: US$1.05 loss per share (vs US$1.17 loss in FY 2024)Full year 2025 results: US$1.05 loss per share. Net loss: US$146.9m (loss widened 29% from FY 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
Board Change • Mar 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Mar 02Dbv Technologies Highlights Additional Data from Successful Phase 3 Vitesse Study At the Aaaai 2026 Annual MeetingDBV Technologies announced that the company shared additional positive data from the successful Phase 3 VITESSE clinical trial as an oral presentation at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting, in Philadelphia, PA. VITESSE, the food allergy immunotherapy trial to date, is a Phase 3 study assessing DBV's VIASKIN®? Peanut Patch for the treatment of peanut-allergic children aged 4 to 7 years. The VITESSE study met its primary endpoint whereby VIASKIN®?Peanut demonstrated a statistically significant treatment effect (pp. The increases in eliciting dose seen are clinically meaningful and may reflect a reduced risk of an allergic reaction. Conversely, nearly four times as many children on placebo saw their eliciting dose decrease, becoming more sensitized over the twelve-month period. These results not only support the VIASKIN®? peanut Patch as a potential treatment option for peanut-allergic children, if approved, but also reinforce the importance of prioritizing a proactive treatment for this specific patient population.
Board Change • Dec 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Nov 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Nov 04DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial, Effective November 3, 2025DBV Technologies announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin(R) Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA submission for 1-3 year-olds in the second half of the year. Kevin Trapp is an accomplished commercial executive with more than 30 years of experience in the biopharmaceutical industry. Before rejoining DBV, Kevin served as a consultant to the Company in his most recent role as Managing Director at Biotech Value Advisors (BVA) where he advised biotechnology boards of directors and executive leadership with product strategy, launch planning, and business evaluation. He built his career at Bristol-Myers Squibb (BMS), where he held roles of increasing responsibility across finance, sales, marketing, and general management. During his time at BMS, he managed a ~$4 billion U.S. specialty and primary care portfolio and was a key stakeholder in the planning and subsequent launches of more than 10 products and indications - including Abilify(R), Atripla(R), Reyataz(R), Orencia(R), and Daklinza(R). Mr. Trapp earned a bachelor's degree from the University of Connecticut School of Business and completed the General Management Program from the European Centre for Executive Development (CEDEP) at INSEAD.
New Risk • Oct 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$98m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$98m free cash flow). Shares are highly illiquid. Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$81m net loss in 3 years).
Reported Earnings • Oct 31Third quarter 2025 earnings released: US$0.24 loss per share (vs US$0.32 loss in 3Q 2024)Third quarter 2025 results: US$0.24 loss per share. Net loss: US$33.2m (loss widened 8.9% from 3Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Europe.
Board Change • Oct 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Oct 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Tim Morris was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Sep 19DBV Technologies Announces Resignation of Daniel Soland as a Member of its Board of Directors, Effective September 18, 2025DBV Technologies announced the resignation of Daniel Soland, as a member of its Board of Directors, effective September 18, 2025.